November 2019, Volume 5, Issue 13

November 2019

Volume 5, Issue 13

This issue explores treating older patients with frailty, discusses the management of primary mediastinal B-cell lymphoma, and more.

Table of Contents

November 2019 Issue

Grief Tacos

Friday, November 1st, 2019
Life is hard. People are resilient. I gave birth to our second son this past February. There are some things about the second kid that...

November 2019 Issue

The Society Pages

Remembering Thomas P. Stossel, CPRIT Awards $136 Million in 71 New Grants, and more

Friday, November 1st, 2019
Remembering Thomas P. Stossel (1941 – 2019) Thomas P. Stossel, MD, former president of the American Society of Hematology (ASH), passed away unexpectedly on September...
ASH Directions

ASH Announces Three New Executive Committee Members, Free Childcare at the 2019 ASH Annual...

Friday, November 1st, 2019
Congratulations to ASH’s Three New Executive Committee Members The American Society of Hematology (ASH) has announced the election of three new members to its Executive...

November 2019 Issue

Staging the Aging

Friday, November 1st, 2019
Routine assessment of frailty can help clinicians tailor treatments and supportive care to an individual patient’s needs Hematologic malignancies are often diseases of older adults...

Pulling Back the Curtain: Jane Little, MD

Friday, November 1st, 2019
In this edition, Jane Little, MD, recounts growing up as one of six children, learning from her colleagues in the Pasta and Red Cell...

November 2019 Issue

You Make the Call

You Make the Call: Is upfront transplant appropriate for this patient with a rare...

Friday, November 1st, 2019
This month, Mitchell Smith, MD, PhD, discusses the role of transplant in gamma-delta T-cell lymphoma. And don't forget to check out next month's clinical dilemma...
How I Treat In Brief

How I Treat In Brief: Primary Mediastinal B-Cell Lymphoma

Friday, November 1st, 2019
Recently, Lisa Giulino-Roth, MD, from Weill Cornell Medical College in New York, discussed the management of primary mediastinal B-cell lymphoma, a rare subtype of...
You Make the Call

Reader Responses: Is upfront transplant appropriate for this patient with a rare cutaneous T-cell...

Friday, November 1st, 2019
Here’s how readers responded to a You Make the Call question about the role of transplant in gamma-delta T-cell lymphoma. Disclaimer: ASH does not recommend...

November 2019 Issue

Opioid Manufacturers Reach Settlements in State Lawsuits

Friday, November 1st, 2019
Large drug manufacturer Purdue Pharma has agreed to pay $10 billion to settle more than 2,600 lawsuits filed by states, cities, counties, individuals, and...

Heparin-Induced Thrombocytopenia Does Not Appear to Protect Against Major Bleeding

Friday, November 1st, 2019
Patients with heparin-induced thrombocytopenia (HIT), a prothrombotic complication of heparin exposure, are believed to be protected against anticoagulant-associated bleeding, but results from a retrospective analysis...
WIB_icon

Older Patients with iTTP Have Delayed Diagnosis and Higher Mortality Than Younger Counterparts

Friday, November 1st, 2019
Older patients diagnosed with immune thrombotic thrombocytopenic purpura (iTTP) have worse short- and long-term mortality compared with younger patients and the general population, according...
WIB_icon

Eltrombopag Induces Complete Platelet Responses in Patients with Lymphoproliferative Disorders and Treatment-Resistant ITP

Friday, November 1st, 2019
Results from a small phase II trial suggest that treatment with eltrombopag was associated with sustained platelet responses and complete responses (CRs) in patients...
WIB_icon

Study Identifies Familial Risk Patterns of Several Hematologic Malignancies

Friday, November 1st, 2019
People who have a first-degree relative diagnosed with a hematologic malignancy have a higher risk of developing a blood cancer, according to an analysis...

With PET-Guided Treatment, Can Radiation Be Eliminated in Early-Stage HL?

Friday, November 1st, 2019
Combined modality treatment (CMT) consisting of chemotherapy and small-field radiotherapy has long been considered the standard of care for patients with early-stage, favorable Hodgkin...

FDA Places Trials of MCL-1 Inhibitor on Clinical Hold

Friday, November 1st, 2019
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on a phase I, dose-escalation study of AMG 397, an oral, small...

Case Report Shows CRISPR-Based Gene Editing Feasible for HIV-Infected Patient

Friday, November 1st, 2019
In a case study published in the New England Journal of Medicine, researchers successfully used a CRISPR-based gene-editing approach in a patient with HIV...

Cardiovascular Events Common With Proteasome Inhibitor Therapy for Previously Treated Multiple Myeloma

Friday, November 1st, 2019
Cardiovascular adverse events (CVAEs) commonly occur during proteasome inhibitor (PI) therapy for relapsed/refractory multiple myeloma (MM), particularly in patients with elevated natriuretic peptides or...

Insurers Propose Coverage of Expensive Gene Therapies

Friday, November 1st, 2019
Large health insurers have unveiled new payment models to make gene therapies – which offer a one-time cure for patients with life-threatening and rare...

FDA Urges Companies to Stop Reporting Gene-Drug Links to Patients

Friday, November 1st, 2019
The U.S. Food and Drug Administration (FDA) is advising genetic testing companies against reporting interactions between DNA findings and drug efficacy or side effects...

Fedratinib Now Approved for Primary or Secondary Myelofibrosis

Friday, November 1st, 2019
The U.S. Food and Drug Administration (FDA) has approved fedratinib to treat intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis....

November 2019 Issue

On location

Carfilzomib-Based Quadruplet Regimen Beats Triplet Approach in Newly Diagnosed Myeloma

Friday, November 1st, 2019
Induction with the quadruplet regimen of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) led to deeper responses and longer progression-free survival (PFS) in patients with...
On location

Subcutaneous and Intravenous Daratumumab Have Similar Safety, Efficacy in Previously Treated and Newly Diagnosed...

Friday, November 1st, 2019
A subcutaneous formulation of daratumumab, plus standard-of-care treatment, led to response rates that were similar to those seen with intravenous daratumumab in patients with...
On location

Can Immunomodulatory Drugs Overcome CHIP’s Effects in Post-Transplant Multiple Myeloma?

Friday, November 1st, 2019
Patients with multiple myeloma (MM) who harbor somatic mutations in hematopoietic cells, known as clonal hematopoiesis of indeterminate potential (CHIP), have better post–autologous hematopoietic...

SHARE